Age Related Macular Degeneration, Choroidal Neovascularization
Conditions
Keywords
neovascularization
Brief summary
Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab) with a significant improval of visual acuity. In our institution we evaluated efficacy of bevacizumab in several pathologies but we dont know what would be the results if we use the same dose several times. Our purpose was to determine the efficacy of bevacizumab for improve or stabilize visual acuity with two or more intravitreal inyections of bevacizumab.
Interventions
Sponsors
Asociación para Evitar la Ceguera en México
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to 95 Years
Healthy volunteers
No
Inclusion criteria
* \* Any visual acuity * OCT: Central foveal thickness greater than 300 u or with evidence of subretinal fluid. * Active angiogram leakage
Exclusion criteria
* \* Basal Inflammatory disease * Endoftalmitis history * Lesions bigger than 5400 u or with scarring greater than 50% of lesion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best corrected visual acuity, OCT foveal thickness and fluorescein angiogram | — |
Countries
Mexico
Outcome results
None listed